Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/2 Trial Investigating the Safety and Efficacy of Autologous TAC T Cell Monotherapy, and TAC T Cells in Combination With Pembrolizumab, in Relapsed HER2-Positive Solid Tumors

NCT04727151 is registered in ClinicalTrials.gov with Triumvira Immunologics, Inc. as lead sponsor.

NCT NCT04727151
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04727151 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/2 Trial Investigating the Safety and Efficacy of Autologous TAC T Cell Monotherapy, and TAC T Cells in Combination With Pembrolizumab, in Relapsed HER2-Positive Solid Tumors
Lead sponsor
Triumvira Immunologics, Inc.
Phase
Phase 1/2
Overall status
Terminated
Start date
April 19, 2021
Completion date
March 25, 2024
Enrollment
28 (actual)
Sites
11

Conditions

As the registry lists them; a condition with its own page is linked.

her2 positive gastric cancer, metastatic her2 positive gastroesophageal junction cancer